For its second fiscal quarter (ending June 30), Weyco Group Inc (NASDAQ: WEYS) has reported a 18% increase in E.P.S. from $0.51 a year ago to $0.60 in the current quarter. For the latest four […]
Voyager Therapeutics Inc (NASDAQ: VYGR) has reported E.P.S. of $-0.18 for its second fiscal quarter (ending June 30) versus $-0.51 for the same period a year ago. This result exceeded the consensus estimate of $-0.40 […]
Theravance Biopharma Inc (NASDAQ: TBPH) stock suffered a major decline of -18.4% on 8/6/24. The shares closed at $7.83. Moreover, this decline was accompanied by exceptionally high trading volume at 515% of normal. The stock […]
Recent extremely meaningful negative changes in investment behavior have impacted Strategic Education Inc (NASDAQ: STRA): the stock’s recent price decline challenged its longer term uptrend, and its shorter term price trend turned down. Strategic Education […]
Puma Biotechnology Inc (NASDAQ: PBYI) stock enjoyed a major increase of 12.3% on 8/6/24. The shares closed at $4.03. Moreover, trading volume in this advance was above average at 142% of normal. The stock has […]
For its second fiscal quarter (ending June 30), Masimo Corp (NASDAQ: MASI) has reported a 0% change in E.P.S. from $0.30 a year ago to $0.30 in the current quarter. This performance was $-0.47 short […]
For its second fiscal quarter (ending June 30), MacroGenics Inc (NASDAQ: MGNX) has reported a -196% decline in E.P.S. from $0.93 a year ago to $-0.89 in the current quarter. This performance was $-0.30 short […]
Ligand Pharmaceuticals Inc (NASDAQ: LGND) has reported a loss for its second fiscal quarter (ending June 30) of $-2.88 versus $0.13 for the same period a year ago — a decline of -2315%. This result […]
Inogen Inc (NASDAQ: INGN) has reported a loss for its second fiscal quarter (ending June 30) of $-0.24 versus a loss $-0.42 for the same period a year ago. This result exceeded the consensus estimate […]
HUTCHMED (China) Limited (NASDAQ: HCM) stock closed at $20.22 on 8/6/24 after a major increase of 10.9%. Moreover, above average trading volume at 127% of normal accompanied the advance. The stock has risen 10.6% during […]
Privacy Statement Terms Of Use ©2024 PriceTarget Research